{"disease":{"id":"nsclc-non-small-cell-lung-cancer","name":"nsclc non small cell lung cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06684418","title":"Artificial Intelligence-based Model for the Prediction of Occult Lymph Node Metastasis and Improvement of Clinical Decision-making in Non-small Cell Lung Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06613633","title":"Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC","phase":"","overall_status":"COMPLETED","enrollment_count":4000,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06751108","title":"Impact of Concomitant Use of Steroids and Immune-Checkpoint Inhibitors on Survival Outcomes in NSCLC Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Seoul National University","has_results":false},{"nct_id":"NCT07222566","title":"Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1410,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06604689","title":"AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06617416","title":"A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":560,"lead_sponsor_name":"Akeso","has_results":false},{"nct_id":"NCT07150598","title":"Immune-Marker Platform for Patients With Advanced Lung Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Technische Universität Dresden","has_results":false},{"nct_id":"NCT07288632","title":"Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"University Of Perugia","has_results":false},{"nct_id":"NCT07524257","title":"ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":494,"lead_sponsor_name":"ImmunityBio, Inc.","has_results":false},{"nct_id":"NCT07242274","title":"Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":472,"lead_sponsor_name":"Jemincare","has_results":false},{"nct_id":"NCT02000947","title":"A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":459,"lead_sponsor_name":"MedImmune LLC","has_results":false},{"nct_id":"NCT06881784","title":"Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":420,"lead_sponsor_name":"Revolution Medicines, Inc.","has_results":false},{"nct_id":"NCT06545331","title":"Study of XB010 in Subjects With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":396,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT06876402","title":"Gene Molecular Alterations as Disease Prognostic Markers in Patients With Non-small Cell Lung Cancer (NSCLC)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":367,"lead_sponsor_name":"Hellenic Cooperative Oncology Group","has_results":false},{"nct_id":"NCT07400575","title":"Anlotinib in Cross-line Treatment of NSCLC and SCLC","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":350,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT03207867","title":"A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":315,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04585750","title":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"PMV Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT07491211","title":"Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05014815","title":"Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":272,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT06954259","title":"Prognostic Correlation Between the Ratio of the Neutrophil Ratio to the Ratio of CD4+/CD8+ T Cells in Patients With Advanced Non-small Cell Lung Cancer NSCLC) Undergoing Immunotherapy Combined With Chemotherapy","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":272,"lead_sponsor_name":"Qiang Xu","has_results":false},{"nct_id":"NCT03562819","title":"Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer).","phase":"","overall_status":"COMPLETED","enrollment_count":268,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07371663","title":"An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":266,"lead_sponsor_name":"Beijing Tide Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT06706076","title":"A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":266,"lead_sponsor_name":"BlossomHill Therapeutics","has_results":false},{"nct_id":"NCT07277413","title":"A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"IDEAYA Biosciences","has_results":false},{"nct_id":"NCT06682793","title":"A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"A2 Biotherapeutics Inc.","has_results":false},{"nct_id":"NCT05652868","title":"Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":227,"lead_sponsor_name":"Mythic Therapeutics","has_results":false},{"nct_id":"NCT07121387","title":"A Retrospective Cohort Analysis of SMARCA4-Deficient Lung Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":221,"lead_sponsor_name":"Shanghai Pulmonary Hospital, Shanghai, China","has_results":false},{"nct_id":"NCT01639001","title":"A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":207,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06727370","title":"Cognitive Screening in Lung Cancer Patients","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"European Institute of Oncology","has_results":false},{"nct_id":"NCT07219251","title":"Engagement of Veterans With Lung Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":194,"lead_sponsor_name":"Palo Alto Veterans Institute for Research","has_results":false},{"nct_id":"NCT07376707","title":"A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":194,"lead_sponsor_name":"Hefei TG ImmunoPharma Co., Ltd.","has_results":false},{"nct_id":"NCT07441941","title":"Single-Fraction Pulmonary Ablative Radiotherapy Outcomes and Quality-of-life Workup","phase":"","overall_status":"RECRUITING","enrollment_count":190,"lead_sponsor_name":"Institut du Cancer de Montpellier - Val d'Aurelle","has_results":false},{"nct_id":"NCT05033691","title":"A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases","phase":"NA","overall_status":"RECRUITING","enrollment_count":162,"lead_sponsor_name":"Hadassah Medical Organization","has_results":false},{"nct_id":"NCT06616766","title":"A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":161,"lead_sponsor_name":"Yuhan Corporation","has_results":false},{"nct_id":"NCT07491497","title":"A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"TRIANA Biomedicines, Inc.","has_results":false},{"nct_id":"NCT05364073","title":"Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":160,"lead_sponsor_name":"ArriVent BioPharma, Inc.","has_results":false},{"nct_id":"NCT05538130","title":"A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":124,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT07469488","title":"A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":122,"lead_sponsor_name":"Shanghai Pulmonary Hospital, Shanghai, China","has_results":false},{"nct_id":"NCT05651022","title":"Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Indaptus Therapeutics, Inc","has_results":false},{"nct_id":"NCT07489066","title":"Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04027647","title":"Phase 2 Study of Dacomitinib in NSCLC","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":118,"lead_sponsor_name":"National Cancer Centre, Singapore","has_results":false},{"nct_id":"NCT07120698","title":"Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"Guangdong Association of Clinical Trials","has_results":false},{"nct_id":"NCT07478809","title":"A Retrospective Real-World Study Based on RATIONALE-307","phase":"","overall_status":"RECRUITING","enrollment_count":109,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT07063329","title":"Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":108,"lead_sponsor_name":"Avistone Pharmaceutical（Ningbo）Co., LTD.","has_results":false},{"nct_id":"NCT07262671","title":"Predictive Value of Exosomes in Pleural Effusion for Advanced Lung Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03444766","title":"Study of Nivolumab for Advanced Cancers in India","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT07008742","title":"Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":false},{"nct_id":"NCT07330596","title":"QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Anhui Provincial Cancer Hospital","has_results":false},{"nct_id":"NCT07285434","title":"Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer","phase":"EARLY_PHASE1","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":90,"lead_sponsor_name":"Biogenea Pharmaceuticals Ltd.","has_results":false},{"nct_id":"NCT01221077","title":"Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":88,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}